Anne-Laure Larroque-Lombard Selected Research

Alkylating Agents

2/2021	Design and Mechanism of Action of a New Prototype of Combi-Molecule "Programed" to Release Bioactive Species at a pH Range Akin to That of the Tumor Microenvironment.
9/2012	"Combi-targeting" mitozolomide: conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anne-Laure Larroque-Lombard Research Topics

Disease

4	Neoplasms (Cancer) 02/2021 - 03/2010
1	Breast Neoplasms (Breast Cancer) 12/2012
1	Prostatic Neoplasms (Prostate Cancer) 09/2012
1	Sarcoma (Soft Tissue Sarcoma) 03/2010

Drug/Important Bio-Agent (IBA)

3	DNA (Deoxyribonucleic Acid)IBA 02/2021 - 03/2010
2	Alkylating AgentsIBA 02/2021 - 09/2012
2	ErbB Receptors (EGF Receptor)IBA 09/2012 - 03/2010
1	MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)IBA 02/2021
1	Chlorambucil (Leukeran)FDA Link 02/2021
1	MitogensIBA 02/2021
1	Proteins (Proteins, Gene)FDA Link 02/2021
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2021
1	2- (2- amino- 3- methoxyphenyl)- 4H- 1- benzopyran- 4- oneIBA 02/2021
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 02/2021
1	AcidsIBA 02/2021
1	Phosphotransferases (Kinase)IBA 01/2015
1	AL622IBA 12/2012
1	mitozolomideIBA 09/2012
1	QuinazolinesIBA 03/2010
1	1- myristoyl- 2- (12- ((5- dimethylamino- 1- naphthalenesulfonyl)amino)dodecanoyl)- sn- glycero- 3- phosphocholineIBA 03/2010
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 03/2010

Therapy/Procedure

1	Therapeutics 01/2015